An approval would give the immunotherapy another big leg up on Bristol Myers Squibb's similar treatment Opdivo.
News & Analysis: Merck & Co.
Pfizer, Merck, and Eli Lilly Will Pay Their Doctors to Get Back to Treating Patients During the COVID-19 Pandemic
The pharma giants want to help any way they can, and that means letting their thousands of medical professionals go where they are most urgently needed.
Merck's Gefapixant could become the first FDA approved drug for chronic cough.
Newer treatments have made an impact.
Merck announced earlier this month that it would be creating a new company so it can focus on key growth areas.
It's a big loss for the healthcare giant, which now needs to find a replacement.
The old dosing regimen will still be available for patients.
Keytruda will continue to be a growth driver for Merck, but the company is looking elsewhere for growth as well.
The World Health Organization is calling it a milestone in Ebola prevention.
Another win for the seeming unstoppable drug -- this time in metastatic triple-negative breast cancer.